`FOR THE DISTRICT OF DELAWARE
`)
`) MDL No. 22-MD-3038 (CFC)
`) ANDA CASE
`
`)
`
`
`
`))
`
`
`PLAINTIFFS’ SECOND AMENDED DISCLOSURES TO DEFENDANTS
`DR. REDDY’S LABORATORIES, LTD. AND DR. REDDY’S
`LABORATORIES, INC. PURSUANT TO RULE 26(a)(1) OF THE
`FEDERAL RULES OF CIVIL PROCEDURE
`Pursuant to Fed. R. Civ. P. 26(a)(1), Plaintiffs Novo Nordisk Inc. and Novo
`
`Nordisk A/S (collectively, “Plaintiffs”), by their attorneys, hereby provide the
`
`following second amended disclosures to Defendants Dr. Reddy’s Laboratories, Ltd.
`
`and Dr. Reddy’s Laboratories, Inc. (collectively, “DRL”).
`
`These disclosures are based upon information reasonably and presently
`
`available to Plaintiffs, while discovery is ongoing. Plaintiffs reserve the right to
`
`supplement and/or amend these disclosures as necessary upon further investigation
`
`
`CONFIDENTIAL
`INFORMATION – SUBJECT TO
`PROTECTIVE ORDER
`
`)
`)
`) C.A. No. 22-294 (CFC)
`) CONSOLIDATED
`ANDA CASE
`
`
`
`))
`
`))
`
`)))
`
`
`)
`
`
`IN RE: OZEMPIC (SEMAGLUTIDE)
`PATENT LITIGATION
`
`
`________________________________
`NOVO NORDISK INC. and
`NOVO NORDISK A/S,
`
`
`Plaintiffs,
`
`
`v.
`
`
`RIO BIOPHARMACEUTICALS INC.,
`et al.,
`
`Defendants.
`
`Novo Nordisk Exhibit 2010
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00001
`
`
`
`Individual
`Christian Peter Enggaard
`
`Christine Bjørn Jensen
`
`Stephanie DeChiaro
`
`
`
`Vanessa Costain
`
`
`All persons knowledgeable
`
`Subject
`Address
`Fenwick & West LLP Certain information
`concerning research and
`development for
`Ozempic®, including
`the subject matter
`described in U.S. Patent
`Nos. 8,920,383 and
`9,775,953.
`
`Fenwick & West LLP Certain information
`concerning research and
`development for
`Ozempic®, including
`the subject matter
`described in U.S. Patent
`No. 10,335,462.
`
`Fenwick & West LLP Certain information
`concerning regulatory
`matters for Ozempic®.
`
`Fenwick & West LLP Certain information
`concerning sales and
`marketing of Ozempic®.
`
`Dr. Reddy’s
`Laboratories, Ltd.
`(Door No. 8-2-337,
`Road No. 3, Banjara
`Hills, Hyderabad,
`Telangana 500034,
`India)
`
`The DRL Product;
`research and
`development of the
`DRL Product; the DRL
`ANDA; DRL’s decision
`to develop the DRL
`Product and file the
`DRL ANDA; subject
`matter disclosed and
`claimed in U.S. Patent
`Nos. 8,129,343;
`8,920,383; 9,775,953;
`and 10,335,462.
`
`3
`
`Novo Nordisk Exhibit 2010
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00002
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`I hereby certify that on July 28, 2023, I caused the foregoing to be
`
`electronically filed with the Clerk of the Court using CM/ECF, which will send
`
`notification of such filing to all registered participants.
`
`I further certify that I caused copies of the foregoing document to be served
`
`on July 28, 2023, upon the following in the manner indicated:
`
`Dominick T. Gattuso, Esquire
`HEYMAN ENERIO GATTUSO
` & HIRZEL LLP
`300 Delaware Avenue, Suite 200
`Wilmington, DE 19801
`Attorneys for Defendants Dr. Reddy’s
`Laboratories, Ltd. and Dr. Reddy’s
`Laboratories, Inc.
`
`Jovial Wong, Esquire
`Sharon Lin, Esquire
`WINSTON & STRAWN LLP
`1901 L Street N.W.
`Washington DC 20036
`Attorneys for Defendants Dr. Reddy’s
`Laboratories, Ltd. and Dr. Reddy’s
`Laboratories, Inc.
`
`Alison M. King, Esquire
`WINSTON & STRAWN LLP
`35 West Wacker Drive
`Chicago, IL 60601-9703
`Attorneys for Defendants Dr. Reddy’s
`Laboratories, Ltd. and Dr. Reddy’s
`Laboratories, Inc.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`VIA ELECTRONIC MAIL
`
`/s/ Travis J. Murray
`
`
`
`
`
`Travis J. Murray (#6882)
`
`
`
`
`
`Novo Nordisk Exhibit 2010
`Dr. Reddy's Laboratories v. Novo Nordisk A/S
`IPR2024-00009
`Page 00003
`
`